Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An announcement from Catheter Precision ( (VTAK) ) is now available.
On October 10, 2025, Catheter Precision held a Special Meeting of stockholders where approximately 43.1% of the outstanding shares of common stock were represented. During the meeting, stockholders approved three proposals: an increase in authorized shares from 60 million to 500 million, the ratification of WithumSmith+Brown, PC as the independent accounting firm for 2026, and the potential adjournment or postponement of the meeting to solicit more votes if necessary.
The most recent analyst rating on (VTAK) stock is a Hold with a $2.50 price target. To see the full list of analyst forecasts on Catheter Precision stock, see the VTAK Stock Forecast page.
Spark’s Take on VTAK Stock
According to Spark, TipRanks’ AI Analyst, VTAK is a Neutral.
The overall stock score reflects significant financial challenges, with persistent losses and negative cash flows being the most impactful factors. Technical analysis provides some neutral signals, but the negative valuation metrics further weigh down the score.
To see Spark’s full report on VTAK stock, click here.
More about Catheter Precision
Average Trading Volume: 1,161,490
Technical Sentiment Signal: Strong Sell
Current Market Cap: $3.84M
For an in-depth examination of VTAK stock, go to TipRanks’ Overview page.
Trending Articles:
- “More Hopeful than Real”: Is a Bidding War Brewing for Warner Bros. Discovery Stock (NASDAQ:WBD)?
- “Didn’t Develop the Way Automakers Thought.” Ford Notches Up, Reconsidering the EV Market
- “Our Focus is Increasingly…on Inference”: Intel Stock (NASDAQ:INTC) Jumps With Crescent Island Testing Next Year